Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D.

Cell. 2010 Mar 5;140(5):652-65. doi: 10.1016/j.cell.2010.01.007.

2.

High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D.

Blood. 2007 Aug 1;110(3):994-1003. Epub 2007 May 2.

3.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D.

Blood. 2008 Jan 15;111(2):816-28. Epub 2007 Oct 9.

4.

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B.

Nat Genet. 2002 Jan;30(1):48-58. Epub 2001 Dec 20.

PMID:
11753385
5.

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A, Gambacorti-Passerini C, Calabretta B, Perrotti D.

Mol Cell Biol. 2002 Apr;22(7):2255-66.

6.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D.

Blood. 2006 Mar 15;107(6):2507-16. Epub 2005 Nov 17.

7.

From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.

Perrotti D, Neviani P.

Clin Cancer Res. 2007 Mar 15;13(6):1638-42. Review.

8.

Control of mRNA translation and stability in haematopoietic cells: the function of hnRNPs K and E1/E2.

Ostareck-Lederer A, Ostareck DH.

Biol Cell. 2004 Aug;96(6):407-11. Review.

PMID:
15384226
9.

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.

Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M.

Blood. 2007 May 15;109(10):4399-405. Epub 2007 Feb 6.

10.

Interplay between miR-574-3p and hnRNP L regulates VEGFA mRNA translation and tumorigenesis.

Yao P, Wu J, Lindner D, Fox PL.

Nucleic Acids Res. 2017 Jul 27;45(13):7950-7964. doi: 10.1093/nar/gkx440.

11.

Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.

Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP.

J Immunol. 2003 Aug 15;171(4):1780-91.

12.

[Effect and possible mechanism of HnRNP E2 decoy RNA on proliferation of K562 leukemia cells].

Chen XM, Feng WL, Zhao SQ, Zeng JM, Bai WJ, Wang XZ, Huang ZG.

Ai Zheng. 2006 Jul;25(7):793-7. Chinese.

PMID:
16831266
13.

Control of translation and miRNA-dependent repression by a novel poly(A) binding protein, hnRNP-Q.

Svitkin YV, Yanagiya A, Karetnikov AE, Alain T, Fabian MR, Khoutorsky A, Perreault S, Topisirovic I, Sonenberg N.

PLoS Biol. 2013;11(5):e1001564. doi: 10.1371/journal.pbio.1001564. Epub 2013 May 21.

14.

Expression patterns of microRNAs associated with CML phases and their disease related targets.

Machová Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T, Moravcová J.

Mol Cancer. 2011 Apr 18;10:41. doi: 10.1186/1476-4598-10-41.

15.

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B.

Blood. 2006 Aug 15;108(4):1353-62. Epub 2006 May 2.

16.

[Targeted blockage of RNA binding protein E2 by decoy RNA induces the granulocytic differentiation of K562 cells].

Chen XM, Feng WL, Xu SX, Zeng JM, Zhao SQ, Luo HW, Bai WJ, Wang XZ, Huang ZG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):34-8. Chinese.

PMID:
18512313
17.

Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.

Shinohara H, Taniguchi K, Kumazaki M, Yamada N, Ito Y, Otsuki Y, Uno B, Hayakawa F, Minami Y, Naoe T, Akao Y.

Cancer Lett. 2015 Apr 28;360(1):28-38. doi: 10.1016/j.canlet.2015.01.039. Epub 2015 Jan 30.

PMID:
25644089
18.

Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm.

Kim JH, Hahm B, Kim YK, Choi M, Jang SK.

J Mol Biol. 2000 May 5;298(3):395-405.

PMID:
10772858
19.

The dual expression of minor and major bcr/abl chimeric mRNA in blast crisis of chronic myelogenous leukemia.

Tanaka M, Yamazaki Y, Hattori M, Tsushita K, Utsumi M, Yoshida S.

Leuk Res. 1996 Jul;20(7):575-80.

PMID:
8795691
20.

bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.

Fujie H, Tsuchiya S, Morita S, Itano M, Yambe T, Ohasi Y, Minegishi N, Minegishi M, Satou T, Konno T.

Leukemia. 1994 Sep;8(9):1592-5.

PMID:
8090037

Supplemental Content

Support Center